Trinity Biotech plc

Trinity Biotech plc is a commercial-stage biotechnology company specializing in the development, manufacture, and marketing of clinical diagnostic products. Headquartered in Bray, Co. Wicklow, Ireland, the company aims to be a leading player in the international diagnostics industry. It also supplies raw materials to the broader life sciences and research sectors.

The company's extensive product portfolio includes diagnostic tests and instrumentation for a wide range of conditions, such as infectious diseases (e.g., HIV, SARS-CoV-2, syphilis), diabetes monitoring (HbA1c), and various autoimmune disorders like Sjögren's syndrome, celiac disease, and lupus. Trinity Biotech serves both clinical laboratory and point-of-care (POC) segments of the diagnostic market, reaching public health authorities, clinical, and reference laboratories globally. Additionally, the company is actively developing continuous glucose monitoring (CGM) products and wearable biosensors, expanding its focus into diabetes management solutions.

Under the leadership of President and CEO John Gillard, appointed in December 2023, Trinity Biotech is undergoing a comprehensive transformation plan aimed at improving profitability and cash flow. Recent developments include successful clinical results for its enhanced EpiCapture™ Prostate Cancer Test and the rollout of its innovative Premier Hb9210 HbA1c Column System, which received a prestigious "Gold" classification for clinical accuracy. The company is also advancing its CGM+ continuous glucose monitoring system towards pivotal trials in 2026. Despite a recent Nasdaq delisting warning due to not meeting minimum market value requirements, Trinity Biotech secured a $25 million equity financing facility to support its strategic initiatives.

Latest updates

Trinity Biotech Appoints Lydon to Drive Commercial Operations Amid Transformation

Event summary

  • Trinity Biotech appointed Jerry Lydon as Head of North America Commercial Operations, effective May 1, 2026.
  • The appointment supports Trinity Biotech's ongoing Comprehensive Transformation Plan, shifting focus to revenue generation and profitability.
  • Q4 2025 revenue was $11.1 million, broadly in line with previous guidance, with gross margin percentage improving.
  • Trinity Biotech’s Premier HbA1c 9210™ platform received the “Gold” classification from the International Federation of Clinical Chemistry for 2026.

The big picture

Trinity Biotech's appointment of Jerry Lydon signals a strategic shift from restructuring to revenue generation following a two-year transformation program. The company's focus on improving commercial execution and profitability comes as the diagnostics market faces increasing pressure to demonstrate value and efficiency. The “Gold” classification for the HbA1c platform provides a near-term boost, but sustained growth will require successful commercialization of new products and navigating ongoing market disruptions.

What we're watching

Execution Risk
The success of Lydon's leadership will hinge on his ability to translate the operational improvements from the transformation plan into tangible revenue growth and profitability within the North American market.
Product Pipeline
Commercialization of EpiCapture and PrePsia will be a key indicator of Trinity Biotech's innovation strategy and ability to expand its diagnostic offerings beyond core products.
Funding Landscape
The company’s revenue remains sensitive to shifts in international aid funding for HIV testing, and future results will depend on navigating this volatile environment.
CID: 3213